Short answer
RAD51C and RAD51D are DNA-repair genes included on many hereditary breast, ovarian, and broad cancer panels. A germline pathogenic or likely pathogenic result is often most important for ovarian, fallopian tube, or primary peritoneal cancer risk discussions, while breast-risk interpretation depends on the exact gene, variant, ancestry, personal history, and family history. A RAD51C or RAD51D VUS is uncertain and should not be treated like a confirmed harmful variant.
How to read the result
| Report wording | Practical meaning | What to ask next |
|---|---|---|
| Pathogenic or likely pathogenic RAD51C variant | The lab found a RAD51C change with enough evidence to be handled as harmful for inherited-risk counseling. | Which ovarian-risk, breast-risk, and family-testing steps are supported for this exact result? |
| Pathogenic or likely pathogenic RAD51D variant | The lab found a RAD51D change with enough evidence to be handled as harmful for inherited-risk counseling. | Does the plan differ from RAD51C for ovarian risk, breast risk, or family testing? |
| RAD51C or RAD51D VUS | The lab found a change, but the cancer-risk meaning is not established. | How should care be based on personal and family history while the variant remains uncertain? |
| Negative RAD51C/RAD51D result | No reportable variant was found in the test performed. | Was there a known family variant, and were BRCA1, BRCA2, BRIP1, PALB2, Lynch genes, and other relevant genes included? |
| Tumor-only RAD51C/RAD51D finding | The result may reflect a cancer-tissue change rather than inherited DNA. | Is separate germline testing needed before relatives are told to test? |
Cancer-risk questions to clarify
- Ovarian, fallopian tube, and primary peritoneal cancer risk is the main RAD51C/RAD51D hereditary cancer discussion, but the plan should still be individualized.
- NCI sources describe RAD51C, RAD51D, and BRIP1 as moderate ovarian-risk genes and note that clinical actionability continues to be refined.
- Breast cancer risk evidence exists, including NCI summaries that place RAD51C and RAD51D in breast cancer panel research, but personal screening decisions should be tied to the exact result and family pattern.
- A result in one of these genes does not automatically explain every breast, ovarian, pancreatic, prostate, or colorectal cancer in a family.
- A negative result is most reassuring when the test was targeted to a known family variant. Without a known family variant, it may be an uninformative negative.
When family history changes the interpretation
Follow-up matters more when RAD51C or RAD51D was found in tumor tissue, when the exact gene and variant need confirmation, or when family history is stronger than the report alone. Genetics counseling can help separate inherited risk from a tumor-only clue and decide whether relatives need targeted testing.
Questions to bring to counseling
- Is this a germline result from blood, saliva, cheek cells, or another normal sample, or was RAD51C/RAD51D found only in tumor testing?
- Which gene is involved, RAD51C or RAD51D, and what is the exact variant notation?
- Is the result pathogenic, likely pathogenic, VUS, likely benign, or benign?
- Which ovarian-risk or risk-reduction conversations are supported for my age and family history?
- Does this result change breast screening, or is breast screening mostly based on family history and other risk factors?
- Do relatives need targeted testing for a known family variant?
- How will I be notified if a RAD51C or RAD51D VUS is reclassified?
When follow-up matters more
Follow-up matters more when RAD51C or RAD51D was found in tumor tissue, when the exact gene and variant need confirmation, or when family testing decisions depend on a known familial change. Paired tumor-normal testing or genetics review can help separate inherited risk from a tumor-only clue.
FAQ
Are RAD51C and RAD51D mainly about ovarian cancer risk?
Yes, ovarian risk is usually the main counseling question, although family history can also affect breast-risk discussions.
Does a RAD51C or RAD51D VUS change care?
No. A variant of uncertain significance should not be managed like a confirmed pathogenic variant.
Does a negative result rule out inherited risk?
Not always. A negative result can still be uninformative if the family history is strong or if another gene explains the pattern.
Does tumor-only RAD51C or RAD51D prove inherited risk?
No. A tumor-only finding does not by itself prove germline inheritance.
Should relatives be tested?
If a familial pathogenic RAD51C or RAD51D variant is known, relatives may be offered targeted testing.
What should counseling clarify first?
The exact gene, variant, specimen type, ovarian-risk pattern, and whether breast screening questions are driven by family history or the DNA result itself.
Related guides: BARD1 genetic testing result interpretation, PALB2 genetic testing result interpretation, BRCA VUS result interpretation, BRCA testing vs broad cancer panels, and tumor genomic vs inherited genetic testing.
How can paired tumor-normal testing help with RAD51C or RAD51D?
It can help show whether the change is present in both tumor and normal DNA, which is the difference between inherited risk counseling and a tumor-only finding.